THE MHRA says that in June 2003, it was the first regulatory body to advise that Seroxat should not be used in the treatment of children and adolescents with depressive illness. It said this was because of lack of evidence of effectiveness and an increas
THE MHRA says that in June 2003, it was the first regulatory body to advise that Seroxat should not be used in the treatment of children and adolescents with depressive illness.
It said this was because of lack of evidence of effectiveness and an increased risk of suicidal behaviour in this group.
The MHRA has advised that though there is a slight increase in the risk of suicide in patients taking SSRIs compared to those taking a placebo, the risk is no higher in SSRIs than in other anti-depressants.
It says young adults are at a higher background risk of suicidal behaviour than older adults so young adults treated with SSRIs should be closely monitored.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here